<DOC>
	<DOCNO>NCT00331799</DOCNO>
	<brief_summary>The purpose study explore benefit duloxetine enhance psychological resilience understand relevance inhibit serotonin ( 5HT ) norepinephrine ( NE ) therapeutic response .</brief_summary>
	<brief_title>Pilot Study Duloxetine Psychological Resilience</brief_title>
	<detailed_description>This investigator-initiated , single-site study consist 8 week open-label , fixed-dose treatment duloxetine ( 30mg-60mg/day ) patient Major Depressive Disorder ( MDD ) .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>age 1865 primary diagnosis MDD base Diagnostic Standard Manual ( DSMIV ) criterion assess MINI International Neuropsychiatric Interview MontgomeryAsberg Depression Rating Scale ( MADRS ) score least 20 baseline Minimum Clinical Global Impressions Severity ( CGS ) severity score 4 Ability provide write consent form A negative serum pregnancy test woman childbearing potential Current DSMIV diagnosis bipolar disorder , schizophrenia psychotic disorder , mental retardation pervasive developmental disorder cognitive disorder due general medical condition History substance abuse dependence within last 6 month Suicide risk serious suicide attempt within last year Clinically significant medical condition laboratory abnormality Women childbearing potential unwilling practice acceptable method contraception Subjects need concurrent use psychotropic medication History sensitivity duloxetine History failure respond adequate trial duloxetine ( least 60mg/day 4 week ) Subjects take monoamine oxidase inhibitor ( MAOIs ) Subjects uncontrolled narrowangle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Pharmacotherapy</keyword>
	<keyword>Duloxetine</keyword>
</DOC>